Luminex Corporation Reports Third Quarter 2013 Results

AUSTIN, Texas, Nov. 4, 2013 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced financial and operating results for the third quarter ended September 30, 2013.  Highlights include the following:

(Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO)

  • Consolidated third quarter revenue of $50.8 million
  • Third quarter assay revenue of $16.1 million.  Infectious disease sales comprised approximately 64 percent of total assay sales, with genetic testing representing 36 percent.
  • Third quarter royalty revenue of $9.0 million 
  • Shipments of 280 multiplexing analyzers, which included 135 MAGPIX systems, 128 LX systems, and 17 FLEXMAP 3D systems
  • Cumulative life-to-date multiplexing analyzer shipments of 10,410
  • Realized a gain of $5.4 million from the sale of our minority interest investment in a private company that was acquired by a third party in July 2013
  • Received FDA and European Clearance for an updated version of Comprehensive Genotyping Assay, xTAG® CYP2D6 Kit in July
  • Received FDA and European Clearance for a new personalized Medicine Genotyping Assay, xTAG® CYP2C19 Kit in September
  • Proceeded with the restructuring plan announced during the quarter, focused on the Newborn Screening Group and our Brisbane, Australia office to allow for increased focus on the molecular diagnostics market

"We are disappointed that the reimbursement issues concerning certain tests included in the new molecular diagnostic code system in the U.S., which we commented on during our second quarter call, have not been resolved and continue to affect the entire industry including Luminex, as we experienced a significant order delay from our largest customer at the end of the quarter.  As we evaluate the recently published reimbursement rates for 2014, we agree with our customers' public comments that this is a transient issue and we expect to see resolution in the near future," said Patrick J. Balthrop, president and chief executive officer of Luminex. 

"We strongly believe in our strategic initiatives and that the Company is well-positioned for substantial growth across our entire portfolio when the transient reimbursement problem is resolved.  Among these initiatives is the development of our unique 'sample-to-answer' system, Project ARIES, which will be demonstrated at the upcoming Association for Molecular Pathology Annual Meeting in Phoenix on November 14-16th.  In addition, we are pleased with the progress our direct sales force made during the quarter selling our family of diagnostic tests including GPP, RVP and our recently approved genotyping assay," added Mr. Balthrop.

REVENUE SUMMARY

(in thousands, except percentages)








Three Months Ended






September 30,


Variance


2013


2012


($)


(%)


(unaudited)













System sales

$    7,568


$    8,550


$    (982)


-11%

Consumable sales

12,837


12,898


(61)


0%

Royalty revenue

8,996


7,690


1,306


17%

Assay revenue

16,115


16,439


(324)


-2%

All other revenue

5,264


4,470


794


18%


$  50,780


$  50,047


$     733


1%


















Nine Months Ended






September 30,


Variance


2013


2012


($)


(%)


(unaudited)













System sales

$  21,772


$  23,934


$ (2,162)


-9%

Consumable sales

36,484


35,600


884


2%

Royalty revenue

27,683


23,647


4,036


17%

Assay revenue

56,138


51,246


4,892


10%

All other revenue

16,190


12,620


3,570


28%


$158,267


$147,047


$11,220


8%

 

LUMINEX CORPORATION

REPORTABLE SEGMENT HIGHLIGHTS

(in thousands, except percentages)










Three Months Ended







September 30,


Variance



2013


2012


($)


(%)



(unaudited)





Revenue








Technology and strategic partnerships

$33,335


$31,584


$ 1,751


6%

Assays and related products

17,445


18,463


(1,018)


-6%

   Total Revenue

50,780


50,047


733


1%










Operating income (loss)








Technology and strategic partnerships

9,293


7,205


2,088


29%

Assays and related products

(13,487)


(3,838)


(9,649)


-251%

   Total Operating income (loss)

(4,194)


3,367


(7,561)


-225%





















Nine Months Ended







September 30,


Variance



2013


2012


($)


(%)



(unaudited)





Revenue








Technology and strategic partnerships

$96,352


$91,358


$ 4,994


5%

Assays and related products

61,915


55,689


6,226


11%

   Total Revenue

158,267


147,047


11,220


8%










Operating income (loss)








Technology and strategic partnerships

23,368


21,725


1,643


8%

Assays and related products

(24,073)


(6,264)


(17,809)


-284%

   Total Operating income (loss)

(705)


15,461


(16,166)


-105%

FINANCIAL OUTLOOK AND GUIDANCE

The Company has revised its 2013 annual revenue guidance to a range of between $212 and $217 million from $220 and $230 million.

CONFERENCE CALL

Management will host a conference call to discuss the operating highlights and financial results for the third quarter ended September 30, 2013, at 4:00 p.m. CST/5:00 p.m. EST, Monday, November 4, 2013. The conference call will be webcast live and will be accompanied by a slide presentation, both of which may be accessed at Luminex Corporation's website at http://www.luminexcorp.com.  Simply log on to the web at the address above, go to the Company section and access the Investor Relations link.  Please go to the website at least 15 minutes prior to the call to register, download and install any necessary audio/video software. If you are unable to participate during the live webcast, the call and slides will be archived for six months on the website using the 'replay' link.

Luminex develops, manufactures and markets proprietary biological testing technologies with applications throughout the life sciences industry.  The Company's xMAP system is an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics research markets.  The Company's xMAP technology is sold worldwide and is in use in leading research laboratories as well as major pharmaceutical, diagnostic and biotechnology companies.  Further information on Luminex or xMAP can be obtained on the Internet at http://www.luminexcorp.com.

Statements made in this release that express Luminex's or management's intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements. Forward-looking statements in this release include statements regarding: the expansion of our installed base of multiplexing systems; our efforts to sell our molecular diagnostic products directly to end users; the development progress of our pipeline products, market acceptance of our genetic and infectious disease products, regulatory clearance of our products; the ability of our investment in current initiatives and new products to deliver high performance solutions, and drive long-term value for our shareholders, the financial impact of recent corporate restructuring, status of molecular codes, the impact of delays of Medicare reimbursement on our customers and current and future impact on our business; and, projected 2013 revenue. The words "believe," "expect," "intend," "estimate," "anticipate," "will," "could," "should" and similar expressions are intended to further identify such forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995.  It is important to note that the Company's actual results or performance could differ materially from those anticipated or projected in such forward-looking statements.  Factors that could cause Luminex's actual results or performance to differ materially include risks and uncertainties relating to, among others, market demand and acceptance of Luminex's products and technology, the Company's dependence on strategic partners for development, commercialization and distribution of products, concentration of the Company's revenue in a limited number of strategic partners, fluctuations in quarterly results due to a lengthy and unpredictable sales cycle and bulk purchases of consumables, our ability to sell products directly to end users, our ability to satisfy market needs with products that we sell, Luminex's ability to scale manufacturing operations and manage operating expenses, gross margins and inventory levels, potential shortages of components, competition, the timing of regulatory approvals, the implementation, including any modification, of the Company's strategic operating plans, the uncertainty regarding the outcome or expense of any litigation brought against Luminex, risks relating to Luminex's foreign operations, risks and uncertainties associated with implementing our acquisition strategy and the ability to integrate acquired companies, or selected assets into our consolidated business operations, including the ability to recognize the benefits of our acquisitions, as well as the risks discussed under the heading "Risk Factors" in Luminex's Reports on Forms 10-K and 10-Q, as filed with the Securities and Exchange Commission.  The forward-looking statements, including the financial guidance and 2013 outlook, contained herein represent the judgment of Luminex as of the date of this press release, and Luminex expressly disclaims any intent, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in Luminex's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Contacts:

Harriss T. Currie



Sr. Vice President, Finance and Chief Financial Officer



512-219-8020



hcurrie@luminexcorp.com


 

LUMINEX CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)






September 30,


December 31,


2013


2012


(unaudited)



ASSETS




Current assets:




Cash and cash equivalents

$          57,169


$         42,789

Short-term investments

5,497


13,607

Accounts receivable, net

30,210


33,273

Inventories, net

29,742


29,937

Deferred income taxes

1,603


4,783

Prepaids and other

5,749


4,388





Total current assets

129,970


128,777





Property and equipment, net

32,788


26,229

Intangible assets, net

61,320


65,218

Deferred income taxes

14,462


14,360

Long-term investments

-


3,000

Goodwill

50,853


51,128

Other

4,503


8,463





Total assets

$        293,896


$       297,175





LIABILITIES AND STOCKHOLDERS' EQUITY




Current liabilities:




Accounts payable

$            9,038


$          9,650

Accrued liabilities

11,756


12,866

Deferred revenue

4,949


4,134

Current portion of long term debt

924


1,138





Total current liabilities

26,667


27,788





Long-term debt

788


1,702

Deferred revenue

2,508


2,933

Other

5,038


5,085





Total liabilities

35,001


37,508





Stockholders' equity:




Common stock

41


41

Additional paid-in capital

291,156


293,392

Accumulated other comprehensive gain

585


1,101

Accumulated deficit

(32,887)


(34,867)





Total stockholders' equity

258,895


259,667





Total liabilities and stockholders' equity

$        293,896


$       297,175

 

LUMINEX CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share amounts)


















Three Months Ended


Nine Months Ended


September 30,


September 30,


2013


2012


2013


2012


(unaudited)


(unaudited)









Revenue

$50,780


$50,047


$158,267


$147,047

Cost of revenue

19,999


15,002


51,472


43,830









Gross profit

30,781


35,045


106,795


103,217









Operating expenses:








Research and development

10,346


11,186


34,852


31,467

Selling, general and administrative

21,466


19,462


67,429


53,075

Amortization of acquired intangible assets

1,021


1,030


3,077


3,214

Restructuring costs

2,142


-


2,142


-









Total operating expenses

34,975


31,678


107,500


87,756









(Loss) income from operations

(4,194)


3,367


(705)


15,461

Interest expense from long-term debt

(16)


(40)


(67)


(162)

Other income, net

6,638


25


6,730


124









Income before income taxes

2,428


3,352


5,958


15,423

Income taxes

(1,632)


(1,676)


(3,978)


(7,268)









Net income

$     796


$  1,676


$    1,980


$    8,155









Net income per share, basic

$    0.02


$    0.04


$     0.05


$     0.20









Shares used in computing net income per share, basic

40,752


41,000


40,712


40,995









Net income per share, diluted

$    0.02


$    0.04


$     0.05


$     0.19









Shares used in computing net income per share, diluted

41,919


41,887


41,771


42,117

 

LUMINEX CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)










Three Months Ended


Nine Months Ended


September 30,


September 30,


2013


2012


2013


2012


(unaudited)


(unaudited)

Cash flows from operating activities:








Net income

$     796


$  1,676


$  1,980


$  8,155

Adjustments to reconcile net income to net cash provided by operating activities:








   Depreciation and amortization

3,994


3,613


11,747


10,668

   Stock-based compensation

1,889


2,338


6,733


7,552

   Deferred income tax expense

1,989


1,987


3,415


2,916

   Excess income tax (benefit) expense from employee stock-based awards

(15)


590


274


(2,183)

   Gain on sale of assets

(5,388)


-


(5,305)


-

   Non-cash restructuring charges

3,695


-


3,695


-

   Other

(34)


472


(1,115)


655

Changes in operating assets and liabilities:








   Accounts receivable, net

1,384


(5,043)


3,076


(8,226)

   Inventories, net

1,769


(877)


(1,914)


(2,604)

   Other assets

(415)


(663)


(2,058)


(2,294)

   Accounts payable

2,215


1,637


(718)


1,706

   Accrued liabilities

(1,184)


(792)


(2,727)


(2,007)

   Deferred revenue

439


(330)


409


(237)









Net cash provided by operating activities

11,134


4,608


17,492


14,101









Cash flows from investing activities:








Purchases of available-for-sale securities

(2,997)


(2,994)


(8,489)


(13,489)

Sales and maturities of available-for-sale securities

2,996


13,070


19,632


43,075

Purchase of property and equipment

(6,914)


(2,152)


(15,136)


(7,509)

Business acquisition consideration, net of cash acquired

-


(48,277)


-


(48,277)

Purchase of cost method investment

-


(1,000)


-


(1,000)

Proceeds from sale of assets

9,533


-


9,564


-

Acquired technology rights

-


(51)


(930)


(342)









Net cash provided by (used in) investing activities

2,618


(41,404)


4,641


(27,542)









Cash flows from financing activities:








Payments on debt

-


-


(1,105)


(1,025)

Proceeds from employee stock plans and issuance of common stock

5,973


861


7,891


3,224

Payments for stock repurchases

-


(11,036)


(14,343)


(20,916)

Excess income tax (expense) benefit from employee stock-based awards

15


(590)


(274)


2,183









Net cash provided by (used in) financing activities

5,988


(10,765)


(7,831)


(16,534)









Effect of foreign currency exchange rate on cash

(49)


149


78


179

Change in cash and cash equivalents

19,691


(47,412)


14,380


(29,796)

Cash and cash equivalents, beginning of period

37,478


75,898


42,789


58,282









Cash and cash equivalents, end of period

$57,169


$28,486


$57,169


$28,486

 

LUMINEX CORPORATION

NON-GAAP RECONCILIATION

(in thousands)










Three Months Ended


Nine Months Ended


September 30,


September 30,


2013


2012


2013


2012


(unaudited)


(unaudited)









Net income

$   796


$1,676


$  1,980


$  8,155









Stock-based compensation

1,889


2,338


6,733


7,552

Amortization of acquired intangible assets

1,021


1,030


3,077


3,214

Costs associated with legal proceedings

105


-


358


-

Resolution of molecular diagnostic distribution agreements

-


-


7,000


-

Acquisition and severance costs

216


2,895


1,031


3,419

Restructuring costs

4,343


-


4,343


-

Gain on sale of cost method equity investment

(5,452)


-


(5,452)


-

Contingent consideration adjustments

(1,220)


-


(1,370)


-

Income tax effect of above adjusting items

637


(1,518)


(376)


(2,993)









Adjusted net income

$2,335


$6,421


$17,324


$19,347









Adjusted net income per share, basic

$  0.06


$  0.16


$    0.43


$    0.47









Shares used in computing adjusted net income per share, basic

40,752


41,000


40,712


40,995









Adjusted net income per share, diluted

$  0.06


$  0.15


$    0.41


$    0.46









Shares used in computing adjusted net income per share, diluted

41,919


41,887


41,771


42,117

The Company makes reference in this release to "non-GAAP net income" which excludes the impact of costs associated with the ENZO Life Sciences, Inc. complaint discussed in the Legal Proceedings section of our 10-Q and certain other recurring and non-recurring expenses. The Company believes that excluding these items and their related tax effects from its financial results reflects operating results that are more indicative of the Company's ongoing operating performance while improving comparability to prior periods, and, as such may provide investors with an enhanced understanding of the Company's past financial performance and prospects for the future. This information is not intended to be considered in isolation or as a substitute for income from operations, net income, net income per share or expense information prepared in accordance with GAAP.

SOURCE Luminex Corporation



RELATED LINKS
http://www.luminexcorp.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.